You searched for mscs - Page 3 of 20

Capricor seeks FDA approval of deramiocel for Duchenne based on encouraging data

November 8, 2024 / Professor Paul Knoepfler, Ph.D. / 1 Comment

The cell therapy biotech Capricor recently released new data from their Duchenne Muscular Dystrophy (DMD) trial work. The data have generated excitement in the patient advocacy community. The stock has skyrocketed. How exciting are these new data? CEO Linda Marbán is quite upbeat and I think it’s justified. The firm is now seeking FDA approval […]

Capricor seeks FDA approval of deramiocel for Duchenne based on encouraging data Read More »

Weekly reads: Parkinson’s & the gut, sports, cat stem cells

September 8, 2024 / Professor Paul Knoepfler, Ph.D. / 1 Comment

I’ve met people who are excited about using stem cells for Parkinson’s Disease. Some of these folks have Parkinson’s or are loved ones. Talking to them makes things real. It feel personal and not just scientific. The current treatment options are far away from what is needed for many people. I am optimistic that a

Weekly reads: Parkinson’s & the gut, sports, cat stem cells Read More »

Weekly reads: diabetes, GvHD, Novo Nordisk & regenerative medicine, HDACs

June 2, 2024 / Professor Paul Knoepfler, Ph.D. / 2 Comments

Do many in the regenerative medicine field have favorite types of stem cells? Some seem to think there’s a tension between those working on pluripotent stem cells like iPS cells and those working with MSCs. I don’t see it that way, though. Whatever stem cells work best for a particular condition should be used and,

Weekly reads: diabetes, GvHD, Novo Nordisk & regenerative medicine, HDACs Read More »

Perspectives on new stem cells for paralysis paper & media coverage

April 10, 2024 / Professor Paul Knoepfler, Ph.D. / 5 Comments

A new paper on stem cells for paralysis from a Mayo Clinic team has sparked a bit of legitimate hope but also some hype in the media. The publication was in Nature Communications. It is entitled “Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial.” The approach was direct injection

Perspectives on new stem cells for paralysis paper & media coverage Read More »

Key Mayo Clinic stem cell webpage is overexuberant & outdated

March 21, 2024 / Professor Paul Knoepfler, Ph.D. / 2 Comments

The Mayo Clinic does some great research on stem cells and regenerative medicine. However, at times I’ve felt that a few Mayo researchers are overexuberant. This mainly relates to certain not-yet-proven stem cell and related offerings. Fitting with that perception, the Mayo website also has some inaccurate stem cell content that leans toward overstating things.

Key Mayo Clinic stem cell webpage is overexuberant & outdated Read More »

Weekly reads: Xist & autoimmune disease in women, Crohn’s disease, dumb headline of the week

February 4, 2024 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

Readers of The Niche have asked me many questions about stem cells for autoimmune disease but the puzzle of why women get these conditions more often than men hasn’t come up before here. For instance, why is MS so much more common in women than men? It’s remained somewhat of a mystery over the years.

Weekly reads: Xist & autoimmune disease in women, Crohn’s disease, dumb headline of the week Read More »

Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics

January 14, 2024 / Professor Paul Knoepfler, Ph.D. / 5 Comments

The biotechs Vertex and CRISPR Therapeutics have an interesting relationship as biotechs. They are partners are multiple levels but also are very different as companies including in size. There’s been a key development in one of their partnerships. Before we jump into that, please check out the video version of my 20 stem cell and

Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics Read More »

Search Results for: mscs